Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma
- PMID: 32460431
- DOI: 10.1002/hep.31391
Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma
Abstract
Background and aims: Hepatocytes undergo profound metabolic rewiring when primed to proliferate during compensatory regeneration and in hepatocellular carcinoma (HCC). However, the metabolic control of these processes is not fully understood. In order to capture the metabolic signature of proliferating hepatocytes, we applied state-of-the-art systems biology approaches to models of liver regeneration, pharmacologically and genetically activated cell proliferation, and HCC.
Approach and results: Integrating metabolomics, lipidomics, and transcriptomics, we link changes in the lipidome of proliferating hepatocytes to altered metabolic pathways including lipogenesis, fatty acid desaturation, and generation of phosphatidylcholine (PC). We confirm this altered lipid signature in human HCC and show a positive correlation of monounsaturated PC with hallmarks of cell proliferation and hepatic carcinogenesis.
Conclusions: Overall, we demonstrate that specific lipid metabolic pathways are coherently altered when hepatocytes switch to proliferation. These represent a source of targets for the development of therapeutic strategies and prognostic biomarkers of HCC.
© 2020 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Comment in
-
Letter to the editor: Hepatocyte proliferation peak and β-oxidation in liver regeneration after partial hepatectomy.Hepatology. 2022 May;75(5):1346-1347. doi: 10.1002/hep.32357. Epub 2022 Mar 1. Hepatology. 2022. PMID: 35080251 No abstract available.
-
Reply.Hepatology. 2022 May;75(5):1347-1348. doi: 10.1002/hep.32365. Epub 2022 Feb 11. Hepatology. 2022. PMID: 35080268 No abstract available.
Similar articles
-
Deranged hepatocyte intracellular Ca2+ homeostasis and the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma.Cell Calcium. 2019 Sep;82:102057. doi: 10.1016/j.ceca.2019.102057. Epub 2019 Jul 26. Cell Calcium. 2019. PMID: 31401389 Review.
-
Metabolomic and transcriptomic profiling of hepatocellular carcinomas in Hras12V transgenic mice.Cancer Med. 2017 Oct;6(10):2370-2384. doi: 10.1002/cam4.1177. Epub 2017 Sep 21. Cancer Med. 2017. PMID: 28941178 Free PMC article.
-
RNF43/ZNRF3 loss predisposes to hepatocellular-carcinoma by impairing liver regeneration and altering the liver lipid metabolic ground-state.Nat Commun. 2022 Jan 17;13(1):334. doi: 10.1038/s41467-021-27923-z. Nat Commun. 2022. PMID: 35039505 Free PMC article.
-
Metabolic profiling of normal hepatocyte and hepatocellular carcinoma cells via 1 H nuclear magnetic resonance spectroscopy.Cell Biol Int. 2018 Apr;42(4):425-434. doi: 10.1002/cbin.10911. Epub 2017 Dec 6. Cell Biol Int. 2018. PMID: 29144590
-
Nuclear receptors in regenerating liver and hepatocellular carcinoma.Mol Cell Endocrinol. 2013 Apr 10;368(1-2):108-19. doi: 10.1016/j.mce.2012.06.025. Epub 2012 Jul 9. Mol Cell Endocrinol. 2013. PMID: 22789748 Review.
Cited by
-
The transcription factor ChREBP Orchestrates liver carcinogenesis by coordinating the PI3K/AKT signaling and cancer metabolism.Nat Commun. 2024 Feb 29;15(1):1879. doi: 10.1038/s41467-024-45548-w. Nat Commun. 2024. PMID: 38424041 Free PMC article.
-
Sulfotransferase SULT2B1 facilitates colon cancer metastasis by promoting SCD1-mediated lipid metabolism.Clin Transl Med. 2024 Feb;14(2):e1587. doi: 10.1002/ctm2.1587. Clin Transl Med. 2024. PMID: 38372484 Free PMC article.
-
Dynamic changes in the mouse hepatic lipidome following warm ischemia reperfusion injury.Sci Rep. 2024 Feb 13;14(1):3584. doi: 10.1038/s41598-024-54122-9. Sci Rep. 2024. PMID: 38351300 Free PMC article.
-
Metabolic reprogramming in the tumor microenvironment of liver cancer.J Hematol Oncol. 2024 Jan 31;17(1):6. doi: 10.1186/s13045-024-01527-8. J Hematol Oncol. 2024. PMID: 38297372 Free PMC article. Review.
-
Identification of the key genes and mechanisms associated with transcatheter arterial chemoembolisation refractoriness in hepatocellular carcinoma.World J Clin Oncol. 2024 Jan 24;15(1):62-88. doi: 10.5306/wjco.v15.i1.62. World J Clin Oncol. 2024. PMID: 38292662 Free PMC article.
References
-
- Malato Y, Naqvi S, Schürmann N, Ng R, Wang B, Zape J, et al. Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest 2011;121:4850‐4860.
-
- Allaire M, Nault JC. Type 2 diabetes–associated hepatocellular carcinoma: a molecular profile. Clin Liv Dis 2016;8:53‐58.
-
- Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010;15(Suppl. 4):14‐22.
-
- Cancer Genome Atlas Research Network . Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 2017;169:1327‐1341:e1323.
-
- Teilhet C, Morvan D, Joubert‐Zakeyh J, Biesse A‐S, Pereira B, Massoulier S, et al. Specificities of human hepatocellular carcinoma developed on non‐alcoholic fatty liver disease in absence of cirrhosis revealed by tissue extracts 1 H‐NMR spectroscopy. Metabolites 2017;7:49.
Publication types
MeSH terms
Grants and funding
- MR/P01836X/1/MRC_/Medical Research Council/United Kingdom
- DH_/Department of Health/United Kingdom
- 26813/CRUK_/Cancer Research UK/United Kingdom
- 19013/CRUK_/Cancer Research UK/United Kingdom
- MC UU 12012/2/MRC_/Medical Research Council/United Kingdom
- MR/K0019494/1/MRC_/Medical Research Council/United Kingdom
- MR/K001949/1/MRC_/Medical Research Council/United Kingdom
- MRC MDU/MRC_/Medical Research Council/United Kingdom
- MC UP A90 1006/MRC_/Medical Research Council/United Kingdom
- MC PC 13030/MRC_/Medical Research Council/United Kingdom
- 12077/CRUK_/Cancer Research UK/United Kingdom
- 19924/CRUK_/Cancer Research UK/United Kingdom
- MR/P011705/2/MRC_/Medical Research Council/United Kingdom
- 22585/CRUK_/Cancer Research UK/United Kingdom
- MC_UU_00014/5/MRC_/Medical Research Council/United Kingdom
- 23390/CRUK_/Cancer Research UK/United Kingdom
- C18342/A23390/CRUK_/Cancer Research UK/United Kingdom
- MR/R023026/1/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Medical
